Abstract: Description is provided herein for an embodiment of a method determining a hematocrit-corrected glucose concentration. The exemplary method includes providing a test strip having a reference electrode and a working electrode, wherein the working electrode includes a plurality of microelectrodes and is coated with at least an enzyme and a mediator.

Abstract: The present invention refers to a method for controlling undesired vegetation at a plant cultivation site. The method comprises the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a wild-type hydroxyphenyl pyruvate dioxygenase or a mutated hydroxyphenyl pyruvate dioxygenase (mut-HPPD) which is resistant or tolerant to a coumarone-derivative herbicide and/or a nucleotide sequence encoding a wild-type homogentisate solanesyl transferase or a mutated homogentisate solanesyl tranferase (mut-HST) which is resistant or tolerant to a coumarone derivative herbicide, and then applying an effective amount of said herbicide to said plant cultivation site. The invention further refers to plants comprising mut-HPPD and to methods of obtaining such plants.

Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.

Abstract: A polymer matrix that may coated on an electrode is created by co-crosslinking (1) an adduct of a polyaniline formed by templated oxidative polymerization on a polymer acid; (2) a water-soluble crosslinker; and (3) a redox enzyme. The polymer matrix may be hydrated, and the absorbed water may make it permeable to, for example, glucose. The polyaniline may be polyaniline itself or a substituted polyaniline; the water-soluble crosslinker may be poly(ethylene glycol)diglycidyl ether, and the redox enzyme may be glucose oxidase. The polymer matrix may be produced by co-crosslinking (1) an adduct of an electrically conductive polymer and a polymer acid; (2) a water-soluble crosslinker; and (3) a redox enzyme in a single step at an about neutral pH, curing by drying. After hydration, the crosslinked polymer matrix may form a 3-dimensional glucose-permeable bioelectrocatalyst, catalyzing the electrooxidation of glucose.

Abstract: The present invention relates to methods of determining enzyme activity in a fluid, wherein the activity over time provides a viscosity-change in the fluid, by the use of a device (FIG. 1) equipped with at least one pressure sensor (FIG. 1 (4)) to determine the change in the fluid viscosity over time as a measure of the enzyme activity.

Abstract: The invention relates to methods and kits for determining the toxicity of an agent on a population of eukaryotic cells, particularly human cells. The cells may comprise a nucleic acid construct comprising a DNA damage induced response element operably linked to a sequence encoding a reporter gene. The multiplex methods and kits provide means for distinguishing between genotoxic and cytotoxic agents.

Abstract: Provided herein are isolated laccase enzymes and nucleic acids encoding them. Also provided are mediators for laccase reactions. Also provided herein are methods for using laccases to oxidize lignins and other phenolic and aromatic compounds, such as for bio-bleaching and decolorization of wood pulp under high temperature and pH conditions to facilitate a substantial reduction in use of bleaching chemicals, as well as for treatment of fibers.

Abstract: A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.

Abstract: A highly active L-isoleucine dioxygenase from Bacillus thuringiensis is provided. A method for manufacturing (2S,3R,4S)-4-hydroxy-L-isoleucine or a salt thereof by reacting L-isoleucine in an aqueous solvent in the presence of L-isoleucine dioxygenase and isolating (2S,3R,4S)-4-hydroxy-L-isoleucine is also provided.

Abstract: The invention provides methods and kits for characterizing the activity of a methyltransferase or demethylase. The method involves enzymatically methylating or demethylating in vitro a substrate that is a peptide fragment of a full-length polypeptide, and then non-enzymatically methylating the peptide substrate with methyl groups that differ in molecular weight from the enzymatically added or removed methyl groups. Typically, deuterated or 13C formaldehyde is used to non-enzymatically methylate the substrate. The fully methylated substrate is then characterized by mass spectrometry to determine the ratio of enzymatically produced nonmethyl, monomethyl, and dimethyl residues on the peptide.

Abstract: A method of positively detecting toxic materials within a sample, the method including contacting sub-mitochondrial particles having competent mitochondrial enzymes formed from inner membranes of mitochondria, an electron donor which transmits electrons to an electron transfer system of the sub-mitochondrial particles and the sample, and forming reaction resultants, adjusting a pH of a pH indicator which change color according to a change in pH, adding the pH indicators to each reaction resultant and identifying color changes of the pH indicator. Also provided is a kit for positively detecting toxic materials within a sample.

Abstract: A highly active L-isoleucine dioxygenase from Bacillus thuringiensis is provided. A method for manufacturing (2S,3R,4S)-4-hydroxy-L-isoleucine or a salt thereof by reacting L-isoleucine in an aqueous solvent in the presence of L-isoleucine dioxygenase and isolating (2S,3R,4S)-4-hydroxy-L-isoleucine is also provided.

Abstract: Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.

Abstract: A novel D-serine quantification method that can overcome various disadvantages of a conventional D-serine quantification method; a novel enzyme that can be used in the D-serine quantification method; a gene encoding the enzyme; and the like. Specifically, a novel D-serine dehydratase including (a) a protein having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a protein having an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 1 and having a D-serine dehydratase activity; and a D-serine quantification method including the steps of reacting a sample with the enzyme, quantifying ammonia or pyruvic acid produced by the reaction, and calculating the amount of D-serine in the sample based on a value produced by the quantification.

Abstract: The present invention describes a method for detecting biomolecular interactions said method comprising: (a) selecting an appropriate reporter molecule selected from the group consisting of a protein, a fluorescent protein, a luminescent protein and a phosphorescent protein; (b) effecting fragmentation of said reporter molecule such that said fragmentation results in reversible loss of reporter function; (c) fusing or attaching fragments of said reporter molecule separately to other molecules; followed by (d) reassociation of said reporter fragments through interactions of the molecules that are fused to said fragments; and (e) detecting said biomolecular interactions by reconstitution of activity of the reporter molecule

Abstract: The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.

Abstract: An electrochemical biosensor analysis system is provided for analyzing a sample liquid, comprising a biosensor having an electrode structure made of at least two electrodes, a test field, covering the electrode structure and capable of absorbing the sample liquid, and a defined sample application surface on the top side of the test field. The system also includes an analysis instrument comprising an evaluation unit for determining the desired analysis data. The analysis instrument comprises an AC resistance measuring device for measuring an AC resistance value between two electrodes of the electrode structure by means of an area compensation measurement. The measured AC resistance value is used, in the determination of the analysis data, as a measure of the partial area of the effective electrode structure area wetted by the sample liquid.

Abstract: In one non-limiting aspect, sterilizable reagent materials for diagnostic elements are provided. In other aspects, sterilized diagnostic elements and techniques for the production of the same are disclosed. In one embodiment, a sterilized diagnostic element includes a chemical detection reagent including at least one component that is sensitive to ionizing radiation. The sterilized diagnostic element is also mediator-free and the at least one component sensitive to ionizing radiation is present in a functional form in a proportion of ? 80% based on the total amount of the respective component in the diagnostic element before sterilization. In certain aspects, the at least one component sensitive to ionizing radiation includes one or both of an enzyme and a coenzyme. Other aspects include, but are not limited to, unique methods, techniques, products, systems and devices involving sterilizable reagent materials or sterilized diagnostic elements.

Abstract: The present invention discloses an on-line system, a method for its calibration and simultaneous detection of antibiotic residues and their concentrations in milk. The system comprises a device for lactose hydrolysis to increase the concentrations of glucose and galactose in milk samples at least 10 times to obtain their equal concentrations in all investigated samples and a biosensor array to measure the transient phase decrease of dissolved oxygen concentration caused by the enzymatic oxidation of glucose and galactose. Parameters, characterising the oxidation of glucose and galactose, are calculated for each biosensor on the basis of the transient phase decrease of dissolved oxygen concentration and initial oxygen concentration in milk sample. The combination of different parameters of different biosensors forms a pattern of milk sample and in the presence of antibiotics this combination forms the fingerprints of particular antibiotics.

Abstract: A panel of blood biomarkers for assessing a sepsis condition utilizing an iNOS indicator in combination with one or more indicators of patient predisposition to becoming septic, the existence of organ damage, or the worsening or recovering from a sepsis episode.

Abstract: Chemiluminescent detection of metabolic by-products of inosine and hypoxanthine is used to diagnose ischemic events such as early acute cardiac ischemia.

Abstract: The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase. The amount of hydrogen peroxide generated in the reaction is measured for determination of percentage of glycated hemoglobin in blood samples. The invention provides kits for performing the methods of the invention.

Abstract: This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.

Abstract: An embodiment of the invention relates to a device for detecting an analyte in a sample. The device comprises a fluidic network and an integrated circuitry component. The fluidic network comprises a sample zone, a cleaning zone and a detection zone. The fluidic network contains a magnetic particle and/or a signal particle. A sample containing an analyte is introduced, and the analyte interacts with the magnetic particle and/or the signal particle through affinity agents. A microcoil array or a mechanically movable permanent magnet is functionally coupled to the fluidic network, which are activatable to generate a magnetic field within a portion of the fluidic network, and move the magnetic particle from the sample zone to the detection zone. A detection element is present which detects optical or electrical signals from the signal particle, thus indicating the presence of the analyte.

Abstract: Described herein are novel nucleic acids, proteins and methods that can be used to provide new catalysts with desirable traits for industrial processes. In particular, novel reductases isolated from the environment using PCR methods are described.

Abstract: A colorimetric reagent in the form of nanoparticles, composite nanoparticles, and nanoparticle coatings, including methods of use, methods of preparation, deposition, and assembly of related devices and specific applications. The colorimetric reagent comprises cerium oxide nanoparticles which are used in solution or immobilized on a solid support, either alone or in conjunction with oxidase enzymes, to form an active colorimetric component that reacts with an analyte to form a colored complex. The rate of color change and the intensity of the color are proportional to the amount of analyte present in the sample. Also described is the use of ceria and doped ceria nanoparticles as an oxygen storage/delivery vehicle for oxidase enzymes and applications in biocatalytic processes in anaerobic conditions of interest in biomedicine and bioanalysis.

Abstract: A modified pyrroloquinoline quinone glucose dehydrogenase that exhibits a high selectivity for glucose is provided. A modified pyrroloquinoline quinone glucose dehydrogenase is disclosed in which the amino acid residue G at Position 99 of a pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) represented by SEQ ID NO: 1, or the amino acid residue G at Position 100 of the pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) represented by SEQ ID NO: 3, is substituted by the amino acid sequence TGZN (where Z is SX, S, or N and X is any amino acid residue). The modified PQQGDH of the present invention may additionally comprise one or more mutations selected from the group consisting of Q192G, Q192A, or Q192S; L193X; E277X; A318X; Y367A, Y367F, or Y367W; G451C; and N452X (where X is any amino acid residue).

Abstract: The invention relates to an arrangement, comprising a solid carrier and a matrix arranged on the solid carrier, said matrix comprising at least one enzymatically convertible or modifiable molecule and comprising at least one enzyme that can be released by the conversion or modification of the molecule, said enzyme being capable of converting at least one color-changing substrate located in the matrix and/or on the solid carrier.

Abstract: Enzymatic biosensors and methods of producing distal tips for biosensor transducers for use in detecting one or more analytes selected from organic compounds susceptible to dehalogenation, organic compounds susceptible to oxygenation, organic compounds susceptible to deamination, organosulfate compounds susceptible to hydrolysis, and organophosphate compounds susceptible to hydrolysis are disclosed herein, as well as biosensor arrays, methods of detecting and quantifying analytes within a mixture, and devices and methods for delivering reagents to enzymes disposed within the distal tip of a biosensor.

Abstract: The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase, and peroxidase. The invention provides kits for performing the methods of the invention.

Abstract: The invention provides methods for managing livestock for breeding or production based on one or more measurements of mitochondrial function. Measurement of mitochondrial function may also be correlated with a calculated or known feed efficiency of livestock animals to yield a predicted feed efficiency for the animal. The invention overcomes deficiencies associated with phenotypic assays for predicted breeding and production value.

Abstract: The present invention relates to a compound of the general formula (I) useful in the determining the presence, amount or activity of an enzyme in living cells, a method of preparing said compounds and a kit thereof.

Abstract: The present invention relates to a method, and a kit, for measuring the enzymatic activity of cytochrome P450 comprehensively and with high efficiency and accuracy, wherein an oxygen sensing layer and a cytochrome P450-supporting layer are vertically integrated on a chip, and cytochrome P450 is supported in a hydrophilic polymer matrix in the cytochrome P450-supporting layer, the cytochrome P450 generates NADPH by being irradiated with light in the presence of at least one caged compound selected from the group consisting of caged-NADP and caged-G6P, an enzyme utilizing NADPH as a coenzyme (i.e., cytochrome P450 reductase) and a substrate thereof to supply NADP and/or G6P from the caged compound to generate NADPH to start the reaction between the enzyme and a substrate.

Abstract: The invention relates to a measurement system MS1 provided with a plurality of loading units 10 into which a measurement tool 4 supporting a reagent is loaded. The measurement system MS1 includes reading means 2 for reading information on an analyte provider that includes identification information, and guidance means 11 for guiding the measurement tool 4 to which an analyte derived from the analyte provider has been or is to be applied, to a loading unit that is selected from the plurality of loading units 10 and individually associated with the analyte provider based on the identification information that has been read by the reading means 2. With such configuration, the measurement results obtained from the analyte derived from the analyte provider can be easily associated with the information on the analyte provider that includes the identification information.

Abstract: The present invention discloses a biosensor strip, which comprises: a base plate layer defining a first strip end and a second strip end; a conductive layer being disposed on the base plate layer and partitioned into at least two electrode paths; a reagent containing layer being disposed on the conductive layer and comprising a first through hole that is located at the first strip end and for accommodating a reagent solution, wherein the reagent solution comprises matrix, redox mediator, enzyme, surfactant, and a buffer solution; a channel forming layer being disposed on the reagent containing layer and comprising a gap portion that is located at the first strip end; and a cover layer being disposed on the channel forming layer and comprising a second through hole that exposes the partial area of the gap portion of the channel forming layer.

Abstract: A method of identifying and classifying non-small-cell lung carcinoma in a biological sample includes a first test wherein the expression level of at least one biomarker is measured in a sample, the at least one=biomarker is selected from a first group consisting of chaperonin, 2,3-bisphosphoglycerate mutase, thymidine phosphorylase, and minichromosome maintenance deficient protein 5, and comparing the measured expression levels against a normal expression level, wherein a significant difference diagnoses or aids in the diagnosis of non-small cell lung carcinoma; and a second test wherein the expression level of at least one biomarker is measured in the sample, the at least one biomarker is selected from a second group consisting of selenium binding protein and Napsin A, and comparing the measured expression level against a normal expression level, wherein a significant difference confirms or aids in confirmation of Non-Small Cell Carcinoma.

Abstract: Methods for stabilizing an enzyme by storing the enzyme in the presence of a stabilized coenzyme are disclosed. In addition, an enzyme stabilized with a stabilized coenzyme as well as the use thereof in test elements for detecting analytes are also disclosed. Other aspects include unique compositions, methods, techniques, systems and devices involving enzyme stabilization.

Abstract: A method for distinguishing among a first group of microorganisms belonging to a first taxon of Gram negative bacteria, the first group of bacteria exhibiting a mechanism of resistance to a treatment; a second group of microorganisms belonging to a second taxon of Gram negative bacteria, the second taxon of bacteria being different than said first taxon, and exhibiting a mechanism of resistance to a treatment identical to the mechanism of the first group; and a third group of Gram negative bacteria that is not resistant to the treatment.

Abstract: The invention relates to a multiple-specificity demethylase complex comprising a Jumonji C (JMJC) domain-containing enzyme, a process of its preparation and its use.

Abstract: Described herein are antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical compositions.

Abstract: The invention provides transdermal optical analysis systems, test sensors, methods, and kits for determining the presence and/or concentration of at least one analyte in a fluid sample. The system includes a transdermal test sensor including an aqueous material including at least one analyte selective reagent and at least one optically active moiety. The optical system preferably uses fluorescent spectroscopy to correlate fluorescent emission or adsorption from a dye with the analyte concentration of the sample. An optical light source and/or detector may be housed with the aqueous material in a housing or external to the housing of the aqueous material.

Abstract: A latent fluorophore is derived from salicylic acid, and containing a fluorogenic group and a moiety represented by formula I wherein the fluorogenic group is directly linked to the moiety of formula I or indirectly linked thereto via a linkage structure. In addition, a method of preparing a latent fluorophore, a method of using the same and a kit containing the same are also introduced.

Abstract: An implantable analyte sensor including a sensing region for measuring the analyte and a non-sensing region for immobilizing the sensor body in the host. The sensor is implanted in a precisely dimensioned pocket to stabilize the analyte sensor in vivo and enable measurement of the concentration of the analyte in the host before and after formation of a foreign body capsule around the sensor. The sensor further provides a transmitter for RF transmission through the sensor body, electronic circuitry, and a power source optimized for long-term use in the miniaturized sensor body.

Abstract: Provided are a method of stabilizing a leuco dye storable as a liquid for a long time, a method of reducing nonspecific color development thereof at a time of a color development reaction, and a stable liquid reagent composition using the methods. The inventors of the present invention found that coexistence of the leuco dye with a specific reducing agent resulted in suppression of self color development and its remarkably improved stability in a solution, and that when a color development reaction of the leuco dye with hydrogen peroxide was performed, coexistence of the leuco dye, in a reaction solution, with another dye which had an absorption spectrum not influencing a measurement wavelength of the leuco dye and did not react with hydrogen peroxide suppressed nonspecific color development and lowered a reagent blank value, which was applied to an analytical reagent.

Abstract: The present invention relates to a method for determining the degree of risk of onset of autism, comprising the step of measuring the triglyceride concentration or the cholesterol concentration in a very low-density lipoprotein fraction of plasma or serum isolated from a subject, or the triglyceride concentration or the cholesterol concentration of plasma or serum. In addition, the present invention provides a kit for determining the degree of risk of onset of autism and a method for screening for a candidate substance for agents for treating autism using a non-human mammal, in which the above described method is utilized.

Abstract: A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen, thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.

Abstract: A method for producing a plant with increased yield as compared to a corresponding wild type plant whereby the method comprises at least the following step: increasing or generating in a plant or a part thereof one or more activities of a polypeptide selected from the group consisting of 2-oxoglutarate-dependent dioxygenase, 3-ketoacyl-CoA thiolase, 3?-phosphoadenosine 5?-phosphate phosphatase, 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase, 5OS chloroplast ribosomal protein L21, 57972199. R01.1-protein, 60952769. R01.1-protein, 60S ribosomal protein, ABC transporter family protein, AP2 domain-containing transcription factor, argonaute protein, AT1 G29250.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.

Abstract: Methods of treating a wound, an ulcer and/or a burn responsive to inhibition of xanthine oxidoreductase to thereby reduce uric acid in an animal are provided wherein the methods include topical administration of a therapeutic agent effective for treatment of the wound, the ulcer and/or the burn wherein the therapeutic agent inhibits xanthine oxidoreductase to thereby reduce uric acid in the wound, ulcer and/or burn. Also provided are methods and kits for determining the severity of a wound, a burn and/or an ulcer including the step of detecting one or more of (i) a level of uric acid; (ii) a level of one or more uric acid precursors; and (iii) a presence, or absence of or level of xanthine oxidoreductase.

Abstract: The present invention provides a method of pretreating a sample containing a glycated amine as an analyte, thereby enabling highly reliable measurement of a glycated amine. A glycated amino acid in the sample is degraded by causing a fructosyl amino acid oxidase (FAOD) to act thereon, and thereafter, a FAOD further is caused to act on the glycated amine as the analyte in the sample to cause a redox reaction. The amount of the glycated amine is determined by measuring the redox reaction. The substrate specificity of the FAOD caused to act on the glycated amino acid may be either the same as or different from that of the FAOD caused to act on the glycated amine. When using the same FAOD, a FAOD is caused to act on the glycated amino acid to degrade it, and thereafter, the sample is treated with a protease to inactivate the FAOD and also to degrade the glycated amine.